

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Platinum-Montaur Life Sciences, LLC (Last) (First) (Middle) 152 WEST 57TH STREET, 4TH FLOOR (Street) NEW YORK, NY 10019 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/26/2012	3. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____	5. If Amendment, Date Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.001	7,472,368	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series W Warrant (1)	12/26/2007	12/26/2012	Common Stock	6,000,000	\$ 0.32	D	
Series X Warrant (2)	04/16/2008	04/16/2013	Common Stock	8,333,333	\$ 0.46	D	
Series AA Warrant (3)	07/24/2009	07/24/2014	Common Stock	2,400,000	\$ 0.97	D	
Series B Preferred Stock (4)	06/22/2010	(5)	Common Stock	19,685,400	\$ 3,270	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Platinum-Montaur Life Sciences, LLC 152 WEST 57TH STREET 4TH FLOOR NEW YORK, NY 10019		X		
Platinum Partners Value Arbitrage Fund, LP 152 WEST 57TH STREET 54TH FLOOR NEW YORK, NY 10019		X		

Signatures

/s/ OLIVER JIMENEZ 11/09/2012
Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series W Warrant provides generally that at no time may a holder of the Series W Warrant exercise the Series W Warrant if the number of shares of Common Stock to be issued pursuant to such exercise would exceed, when Warrant. In addition, such provision shall be of no further force or effect during the 61 days immediately preceding the expiration of the term of the Series W Warrant.
- (2) The Series X Warrant provides generally that at no time may a holder of the Series X Warrant exercise the Series X Warrant if the number of shares of Common Stock to be issued pursuant to such exercise would exceed, when Warrant. In addition, such provision shall be of no further force or effect during the 61 days immediately preceding the expiration of the term of the Series X Warrant.
- (3) The Series AA Warrant provides generally that at no time may a holder of the Series AA Warrant exercise the Series AA Warrant if the number of shares of Common Stock to be issued pursuant to such exercise would exceed, when Warrant. In addition, such provision shall be of no further force or effect during the 61 days immediately preceding the expiration of the term of the Series AA Warrant.
- (4) The certificate of designation of the Series B Preferred Stock provides generally that at no time may a holder of shares of Series B Preferred Stock convert shares of the Series B Preferred Stock if the number of shares of Common Stock issuable upon conversion of Series B Preferred Stock.
- (5) No expiration date.

Remarks:

This Form 3 is filed by Platinum-Montaur Life Sciences, LLC and Platinum Partners Value Arbitrage Fund L.P. in respect of securities held directly by them. Each of the reporting entities and their respective officers, members, managers, directors, or persons performing similar functions, are not required to respond to the collection of information contained in this form unless the form displays a currently valid OMB number.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.